Close Menu

NEW YORK (360Dx) – Epic Sciences said today that its lab is now licensed by the New York State Department of Health to provide its Oncotype DX AR-V7 Nucleus Detect test for residents with metastatic castration-resistant prostate cancer.

The assay, which has already been available for patients in other states under the lab's CLIA certification and is marketed by Genomic Health, uses Epic Sciences' proprietary circulating tumor cell platform to identify the presence of AR-V7 protein in these cells' nuclei.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.